AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03176251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gamified-Integrated Curriculum
Description: The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
Study NCT03176251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified-Integrated Curriculum
Description: The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
Study NCT00864214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioidentical hormone (Biest)
Description: Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
Study NCT03888404 — intervention group
Intervention type: OTHER
Intervention: Pregnancy preferences (Aim 3a)
Description: The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
Study NCT03888404 — intervention group
Intervention type: OTHER
Intervention: Pregnancy (Aim 3b)
Description: The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
Study NCT00864214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioidentical hormone (Biest)
Description: Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
Study NCT00864214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioidentical hormone (Biest)
Description: Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
Study NCT00864214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioidentical hormone (Vivelle-Dot)
Description: Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
Study NCT02994979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delirium-prevention
Description: Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients.
Study NCT02994979 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Usual care plus sham visits by CNA
Study NCT00989378 — intervention group
Intervention type: BEHAVIORAL
Intervention: baseline study
Description: normal bedtimes
Study NCT06220682 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The specific genetic PCR laboratory test were performed for all selected patients for eNOS SNPs
Description: using Real-Time PCR (QuantStudioTM 3 Real-Time PCR) with an allele-specific fluorogenic oligonucleotide probe and a TaqMan pre-designed SNP Genotyping assay
Study NCT02241174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Hypochlorite
Description: The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
Study NCT02241174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite
Description: The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
Study NCT03715764 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy assessment
Description: Primary assessment, diagnose and treatment by a physical therapist for patients with knee pain in primary care.
Study NCT03715764 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physician assessment
Description: Primary assessment, diagnose and treatment by a physician for patients with knee pain in primary care.
Study NCT03010163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Fair
Description: Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.
Study NCT03010163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Fair
Description: Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.
Study NCT01572337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Description: Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure
Study NCT01572337 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Study NCT03010163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.
Study NCT04602611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncology Nurse Navigation
Description: Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
Study NCT04082429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concizumab
Description: When patients are randomised/allocated to concizumab prophylaxis, they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week (Wk) 0) (arm 2, 3 and 4) or visit 9a (Wk 24) (arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (Wk 6) or 9a.3 (Wk 30) and will be based on the concizumab exposure level measured at the previous visit 4a (Wk 6) or 9a.2 (Wk 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual replacement therapy until visit 9a (week 24; end of main part). In the extension part, patients in arm 1 will receive daily concizumab subcutaneous injections.
Study NCT04464707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Dose A or Dose B subcutaneous
Study NCT04464707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT04369911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
Study NCT04323553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulsed-field gel electrophoresis and whole genome sequencing
Description: Comparison of the two different techniques
Study NCT04323553 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Demographic data (age, gender, hospital admission and discharge date, rooms and wards with dates of admission and discharge, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel history, recent hospitalization in an ESBL-high burden region, admission from another healthcare facility, admission from a long-term care facility, occupational or household contact to animals) Clinical data (date of diagnosis of ESBL-producing E. coli carriage, type of infection/colonization with ESBL- producing E. coli, comorbidities, Charlson Comorbidity Index, infectious diseases after detection of ESBL-PE, active open wounds, indwelling vascular devices, urinary catheterization) Treatment data (Immunosuppression, antibiotic therapy, concomitant medication and surgical therapy prior to and during hospital stay) Microbiological data
Study NCT03853434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: Angiographic embolization
Study NCT04490109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B244
Description: B244 suspension
Study NCT04490109 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle suspension
Study NCT02582073 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (0.5ml)
Study NCT01751737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Imaging
Description: After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
Study NCT04312399 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood take
Description: Blood is taken to analyse degradation products of the metabolism of amyloid
Study NCT02582073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (0.5ml)
Study NCT02582073 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.5ml)
Study NCT02582073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (1.0ml)
Study NCT02582073 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (1.0ml)
Study NCT02582073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL (0.5ml) 5100SU
Study NCT02582073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL (1.0ml) 10200SU
Study NCT02582073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass MATA MPL (1.0ml) 18200SU
Study NCT02582073 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Grass MATA (0.5ml) 5100SU
Study NCT01746121 — intervention group
Intervention type: GENETIC
Intervention: Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.
Study NCT03018418 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton therapy
Description: Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions
Study NCT03018418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
Study NCT03994250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinematic Alignment for total knee replacement surgery
Description: Using Kinematic Alignment for total knee replacement surgery
Study NCT03994250 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mechanical Alignment for total knee replacement surgery
Description: Using mechanical alignment for total knee replacement surgery
Study NCT04166409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT04166409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT04166409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT04166409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04166409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04166409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04166409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04166409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04166409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04166409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study NCT04166409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03010163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.
Study NCT03010163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Daily healthy living advice and encouraging messages about walking through text messages
Study NCT03010163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Network Support
Description: Family or friends will provide encouragement and remind participants to maintain in a healthy lifestyle and increase daily walking activities
Study NCT01852578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
Study NCT00162201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Parenteral, IV, 500 mg if \< 60 kg; 750 mg if > 60 \& \< 100 kg; 1000 mg if > 100 kg, Monthly, 4 months.
Study NCT02412423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-transplantation cyclophosphamide
Study NCT02733068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Description: 0.5ml of recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast) on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
Study NCT02733068 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HPV-16/18 placebo
Description: 0.5ml of placebo on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
Study NCT01961388 — intervention group
Intervention type: DRUG
Intervention: Bay G5421 Glucobay
Description: Oral, dosage of Acarbose as per the directions of treating physician
Study NCT01961388 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: Oral, dosage of Metformin as per the directions of treating physician
Study NCT00642941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
Study NCT03104517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMDC-USR (iltamiocel)
Description: Autologous Muscle Derived Cells for Urinary Sphincter Repair (generic name: iltamiocel)
Study NCT01999361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: treatment with myfortic
Study NCT04262830 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging (MRI)
Description: Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics
Study NCT04262830 — intervention group
Intervention type: OTHER
Intervention: Accelerometer physical activity monitoring
Description: Measurement of physical activity using hip-worn accelerometer.
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sunitinib
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temsirolimus
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab and Pertuzumab
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vemurafenib and Cobimetinib
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Regorafenib
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab and Ipilimumab
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abemaciclib
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Talazoparib
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab and PHESGO
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab and Talazoparib
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Entrectinib
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Larotrectinib
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tucatinib plus Trastuzumab Subcutaneous (SC)
Description: drug
Study NCT02693535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Futibatinib
Description: drug
Study NCT04178915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bood leukocyte subsets
Description: Determination of blood leukocyte subpopulations, myeloid suppressor cells of various origins, type 2 congenital lymphoid cells, depleted T cells, CD45RA+ CD45RB+ CD62L-IRC, T-cell differentiation stages (naive - memory cells - effector - terminally differentiated effectors), B cells (CD5+ B1 cells, CD11c+ ABC, differentiation stages: immature - naive - isotype-unswitched memory cells - isotype-switched memory cells - plasmoblast)
Study NCT04178915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The cholesterol content of the cell membrane of T-cells and monocytes
Description: The cholesterol content of the cell membrane of T-cells and monocytes with flow cytometry analysis
Study NCT00024622 — intervention group
Intervention type: DRUG
Intervention: 18F-Fluoro-L-dopa
Study NCT00024622 — intervention group
Intervention type: DRUG
Intervention: O-15 Water
Study NCT00640380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve stimulation
Description: CPVB with NS
Study NCT00640380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Loss of resistance to air
Description: CPVB with LOR
Study NCT02816021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
Study NCT02816021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
Study NCT02412891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroShield device
Description: The UroShield device is Consists of two units:Actuator and Driver.
Study NCT02412891 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham UroShield device
Study NCT00962741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg